Compare VYGR & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | TSSI |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.8M | 252.1M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | TSSI |
|---|---|---|
| Price | $4.02 | $8.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 375.7K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.63 |
| EPS | N/A | ★ 0.19 |
| Revenue | $31,316,000.00 | ★ $234,837,000.00 |
| Revenue This Year | N/A | $54.04 |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | ★ N/A | $45.25 |
| Revenue Growth | N/A | ★ 91.66 |
| 52 Week Low | $2.65 | $5.63 |
| 52 Week High | $5.96 | $31.94 |
| Indicator | VYGR | TSSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 50.13 |
| Support Level | $3.89 | $8.13 |
| Resistance Level | $4.19 | $8.90 |
| Average True Range (ATR) | 0.19 | 0.45 |
| MACD | 0.00 | 0.36 |
| Stochastic Oscillator | 50.57 | 81.77 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.